ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS, oprettet i 2005 (United States), fra 496 søstermærker og 17478 konkurrerende mærker. Mærket ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS er ejet af BRISTOL-MYERS SQUIBB COMPANY, et selskab noteret i New York. ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS's sektor er Lægemiddelproducenter.